WO2015080433A1 - Pharmaceutical combination formulation comprising amlodipine, losartan and rosuvastatin - Google Patents

Pharmaceutical combination formulation comprising amlodipine, losartan and rosuvastatin Download PDF

Info

Publication number
WO2015080433A1
WO2015080433A1 PCT/KR2014/011205 KR2014011205W WO2015080433A1 WO 2015080433 A1 WO2015080433 A1 WO 2015080433A1 KR 2014011205 W KR2014011205 W KR 2014011205W WO 2015080433 A1 WO2015080433 A1 WO 2015080433A1
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutically acceptable
losartan
rosuvastatin
amlodipine
acceptable salt
Prior art date
Application number
PCT/KR2014/011205
Other languages
French (fr)
Inventor
Seung Yeop Lee
Ho Taek IM
Myoung Ki Jeong
Yong Il Kim
Jae Hyun Park
Jong Soo Woo
Original Assignee
Hanmi Pharm. Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53199333&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2015080433(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to CA2929862A priority Critical patent/CA2929862A1/en
Priority to RU2016125749A priority patent/RU2660586C1/en
Priority to EP14866739.7A priority patent/EP3073998A4/en
Priority to AU2014354475A priority patent/AU2014354475B2/en
Priority to CN201480064825.8A priority patent/CN105792813B/en
Priority to MX2016006415A priority patent/MX370041B/en
Priority to US15/039,238 priority patent/US9833413B2/en
Application filed by Hanmi Pharm. Co., Ltd. filed Critical Hanmi Pharm. Co., Ltd.
Priority to BR112016011603A priority patent/BR112016011603A2/en
Priority to JP2016531655A priority patent/JP6427572B2/en
Priority to UAA201606918A priority patent/UA120043C2/en
Publication of WO2015080433A1 publication Critical patent/WO2015080433A1/en
Priority to PH12016500833A priority patent/PH12016500833A1/en
Priority to ZA2016/03272A priority patent/ZA201603272B/en
Priority to SA516371218A priority patent/SA516371218B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing

Definitions

  • the present invention relates to a pharmaceutical combination formulation comprising amlodipine, losartan and rosuvastatin. More specifically, it relates to a pharmaceutical combination formulation comprising a first discrete part containing amlodipine and rosuvastatin and a second discrete part containing losartan, which exhibits improved dissolution rate and stability.
  • hypertension cases are categorized as primary hypertension which means high blood pressure with no obvious underlying medical cause.
  • the exact cause of primary hypertension is unknown, but a number of factors including increase in cardiac output (the volume of blood being pumped out by the heart) or peripheral resistance are believed to contribute to the onset of the disease.
  • Risk factors that are related to hypertension include psychological and environmental factors such as drinking, smoking, aging, lack of exercise, obesity, too much salt in the diet, stress and the like. Genetically, when both parents have hypertension, the offspring has an 80% chance of having hypertension; if one of the parents has hypertension, the offspring has a 25 to 50% chance of having hypertension.
  • the ultimate goal in the treatment of hypertension is to maintain an optimal blood pressure to minimize tissue damage caused by hypertension.
  • adopting a preventative lifestyle is as important as taking a medication. It is a goal to keep blood pressure less than 140/90 mmHg for patients with hypertension, and less than 130/80 mml lg for hypertensive patients with diabetic or nephritis complications.
  • hypertension may reduce mortality caused by stroke and cardiovascular disorders.
  • patients with hypertension When patients with hypertension are properly treated, it is estimated that risks of experiencing stroke, myocardial infarction and heart failure are lowered by about 35-40%, 20-25% and more than 50%, respectively.
  • Lowering systolic blood pressure by 5 mmHg reduces all-cause mortality by 7% on a population basis, while mortality for coronary heart disease and stroke can be reduced by 9% and 14%, respectively.
  • blood pressure is closely related to Alzheimer's disease and, thus, blood pressure management may reduce the risk of Alzheimer's disease.
  • a combination of drugs of different mechanisms has an advantage over individual drugs in terms of preventive and therapeutic effect. Also, a combination therapy reduces doses of individual drugs, thereby reducing side effects which may occur due to long-term administration of individual drugs.
  • vasodilators are further categorized in accordance with their mechanism of action, as follows: angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers and calcium channel blockers.
  • ACE angiotensin-converting enzyme
  • hyperlipidemia is a disorder in which an excessively high level of lipids in the blood cause a buildup of plaque on the walls of the arteries, followed by inflammation and, ultimately, cardiovascular disorders.
  • an abnormal amount of lipids in the blood is defined as dyslipidemia.
  • non-drug therapies such as lifestyle changes
  • Statin-based drugs are often used, and these drugs act as an HMG-CoA reductase inhibitor which has an ability to inhibit cholesterol synthesis and thereby to cause significant reduction in plasma LDL-cholesterol levels, and also result in partial reduction in triglycerides levels.
  • Amlodipine is a generic name for
  • amlodipine besylate is commercially available under the trade name Novasc ® .
  • Amlodipine camsylate as disclosed in Korean Patent No. 452491, shows superior solubility and stability to amlodipine besylate, and is currently available under the trade name Amodipin ® .
  • Amlodipine blocks calcium channel, and is useful in the treatment of cardiovascular disorders such as angina, hypertension and congestive heart failure.
  • Losartan is a generic name for
  • losartan potassium is commercially available under the trade name Cozaar ® , By blocking the interaction of angiotensin II and its receptor, losartan is mainly used for treating hypertension, heart failure, ischemic peripheral circulatory disorder, myocardial ischemia (angina pectoris), diabetic neuropathy and glaucoma, and also for preventing the progression of post-myocardial infarction heart failure.
  • a combination formulation of amlodipine and losartan that have different mechanism of action from each other has an advantage over the individual drugs in terms of preventive and therapeutic effect.
  • such formulation reduces doses of the individual drugs, thereby decreasing side effects which may occur due to a long-term administration of the individual drugs.
  • the combination formulation is disclosed in Korean Patent Nos. 1 160151, 1232296, etc., and currently sold under the trade name Amosartan .
  • the co-occurrence rate of hypertension and hyperlipidemia is approximately 49%, and co-administration of Amosartan ® and statin-based drugs takes up about 30% in the drug treatment of cardiovascular disorders.
  • the present inventors have conducted intensive research to redress the problems of the conventional formulations, and found that dissolution rate and stability of the active ingredients varied depending on the structure of a bilayer tablet and the manufacturing method thereof, and thus accomplished a pharmaceutical combination formulation comprising amlodipine, losartan and rosuvastatin having improved dissolution rate and stability.
  • a pharmaceutical combination formulation for the treatment of a cardiovascular disorder comprising amlodipine, losartan and rosuvastatin, having different action mechanisms from one another, which exhibits excellent dissolution and stability properties.
  • a pharmaceutical combination formulation for the prevention or treatment of a cardiovascular disorder comprising: (1) a first discrete part comprising amlodipine or a pharmaceutically acceptable salt thereof, rosuvastatin or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable additive; and (2) a second discrete part comprising losartan or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable additive, wherein said discrete parts are physically separated from each other.
  • the pharmaceutical combination formulation comprising amlodipine, losartan and rosuvastatin can be effectively used to prevent or treat a cardiovascular disorder. Designed to minimize an interaction among active ingredients, the pharmaceutical combination formulation exhibits excellent storage stability and dissolution rates of amlodipine, losartan and rosuvastatin, and thus can be useful in pharmaceutical industries.
  • Fig. 1 is a schematic view showing a bilayer tablet according to one embodiment of the present invention.
  • Fig. 2 is a graph showing dissolution rate of amlodipine in the formulations of Example 1 and Comparative Example 1.
  • Fig. 3 is a graph showing dissolution rate of rosuvastatin in the formulations of Example 1 and Comparative Example 1.
  • Fig. 4 is a graph showing dissolution rate of losartan in the formulations of Example 1 and Comparative Example 1.
  • Fig. 5 is a graph showing dissolution rate of amlodipine in the formulations of Example 1 and Comparative Example 2.
  • Fig. 6 is a graph showing dissolution rate of rosuvastatin in the formulations of Example 1 and Comparative Example 2.
  • Fig. 7 is a graph showing dissolution rate of losartan in the formulations of Example 1 and Comparative Example 2.
  • Fig. 8 is a graph showing dissolution rate of amlodipine in the formulations of Examples 1 to 3 and Comparative Examples 3 to 5.
  • Fig. 9 is a graph showing dissolution rate of rosuvastatin in the formulations of Examples 1 to 3 and Comparative Examples 3 to 5. ?
  • Fig. 10 is a graph showing dissolution rate of losartan in the formulations of Examples 1 to 3 and Comparative Examples 3 to 5.
  • Fig. 1 1 is a graph showing dissolution rate of amlodipine in the formulations of Example 1 and Comparative Examples 6 and 7.
  • Fig. 12 is a graph showing dissolution rate of rosuvastatin in the formulations of Example 1 and Comparative Examples 6 and 7.
  • Fig. 13 is a graph showing dissolution rate of losartan in the formulations of Example 1 and Comparative Examples 6 and 7.
  • Fig. 14 is a graph showing dissolution rate of amlodipine in. the formulations of Examples 4 to 6 and Comparative Examples 8 to 10.
  • Fig. 15 is a graph showing dissolution rate of rosuvastatin in the formulations of Examples 4 to 6 and Comparative Examples 8 to 10.
  • Fig. 16 is a graph showing dissolution rate of losartan in the formulations of Examples 4 to 6 and Comparative Examples 8 to 10.
  • the present invention provides a pharmaceutical combination formulation for the prevention or treatment of a cardiovascular disorder, comprising: (1) a first discrete part comprising amlodipine or a pharmaceutically acceptable salt thereof, rosuvastatin or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable additive; and (2) a second discrete part comprising losartan or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable additive, wherein said discrete parts are physically separated from each other.
  • the combination formulation according to the present invention comprises the first and the second discrete parts in which said discrete parts are physically separated, i.e., amlodipine and losartan are separately contained.
  • amlodipine and losartan are separately contained.
  • the first discrete part and the second discrete part in the combination formulation may be a first layer and a second layer, respectively.
  • the combination formulation may be in the form of a bilayer tablet comprising: (1) a first layer comprising amlodipine or a pharmaceutically acceptable salt thereof, rosuvastatin or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable additive; and (2) a second layer comprising losartan or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable additive (see Fig. 1).
  • the combination formulation may be prepared in various forms where a first discrete part and a second discrete part are physically separated from each other (for example, core-shell structure).
  • the combination formulation of the present invention comprises amlodipine or a pharmaceutically acceptable salt thereof in the first discrete part (or the first layer).
  • the pharmaceutically acceptable salt of amlodipine employed in the present invention may be prepared by using an acid containing a pharmaceutically acceptable anion which can form a non-toxic acid addition salt, e.g., hydrogen chloride, hydrogen bromide, sulfate, phosphate, acetate, malate, furmarate, lactate, tartrate, citrate, gluconate, besylate and camsylate, but are not limited thereto.
  • the pharmaceutically acceptable salt of amlodipine is amlodipine besylate and camsylate, more preferably camsylate.
  • amlodipine of . the present invention includes a racemic mixture and (S)-amlodipine. Amlodipine or a pharmaceutically acceptable salt thereof may be administered at a daily dose of from 5 to 10 mg.
  • the combination formulation of the present invention comprises rosuvastatin or a pharmaceutically acceptable salt thereof in the first discrete part (or the first layer).
  • the pharmaceutically acceptable salt of rosuvastatin include inorganic salts having polycation, preferably rosuvastatin calcium, but are not limited thereto. Rosuvastatin or a pharmaceutically acceptable salt thereof may be administered at a daily dose of from 10 to 20 mg.
  • the combination formulation of the present invention comprises losartan or a pharmaceutically acceptable salt thereof in the second discrete part (or the second layer).
  • examples of the pharmaceutically acceptable salt of losartan include losartan potassium, but are not limited thereto.
  • Losartan or a pharmaceutically acceptable salt thereof may be administered at a daily dose of from 45 to 100 mg.
  • amlodipine or a pharmaceutically acceptable salt thereof, rosuvastatin or a pharmaceutically acceptable salt thereof and losartan or a pharmaceutically acceptable salt thereof may be admixed in a weight ratio of 1 : 1-4 : 10-20, but not limited thereto.
  • the first discrete part (or the first layer) arid the second discrete part (or the second layer) of the combination formulation may further comprise a pharmaceutically acceptable additive, e.g., a pharmaceutically acceptable ; . carrier or excipient.
  • a pharmaceutically acceptable carrier or excipient include lactose (lactose hydrate), micro-crystalline cellulose, mannitol, sodium citrate, ⁇ 3 ⁇ citrate, calcium phosphate, glycine and starch, a disintegrant (e.g., crospovidone, copovidone, sodium starch glycolate, croscarmellose sodium, and combination silicates) and a binder (e.g. , polyvinylpyrrolidone, hydroxypropyl methyl cellulose (HPMC), hydroxypropyl cellulose (HPC), sucrose, gelatin and acacia gum.
  • lactose lactose hydrate
  • micro-crystalline cellulose mannitol
  • mannitol sodium cit
  • the combination formulation of the present invention comprises lactose hydrate and micro-crystalline cellulose in the first discrete part (or the first layer) as additives.
  • the lactose hydrate may be comprised in an amount of from 20 to 40 wt% based on the total weight of the first discrete part (or the first layer).
  • the micro-crystalline cellulose may be comprised in an amount of from 50 to 70 wt% based on the total weight of the first discrete part (or the first layer).
  • the lactose hydrate and micro-crystalline cellulose may be employed in a ratio of 1 : 1.5 to 1 :3.
  • the lactose hydrate When the lactose hydrate is employed in said range, the lactose hydrate may form hydrophilic channels which promote dissolution of active ingredients, thereby allowing a fast dissolution.
  • a fast dissolution profile cannot be obtained if the amount falls below said range, and if the amount exceeds said range, time required for complete dissolution of the lactose hydrate is extended and thereby slowing down the dissolution of active ingredients.
  • the tableting process becomes easy if the micro-crystalline cellulose is employed in said range.
  • an amount smaller than said range may cause some difficulties during the tableting process, whereas an excessive amount may lead to an excessively large size of formulation.
  • dissolution rates of amlodipine, rosuvastatin and losartan may be improved significantly by employing the lactose hydrate and micro-crystalline cellulose in said range.
  • the second discrete part (or the second layer) of the inventive combination formulation may be prepared in a conventional manner, e.g., compaction granulation followed by tableting.
  • the second discrete part is in the form of granules prepared by a dry roller compaction process.
  • a problem of gelation of losartan occurs when a combination formulation is prepared by simply mixing amlodipine, rosuvastatin and losartan.
  • Losartan readily dissolves in purified water and is easily released at a relatively high pH (e.g., pH 4.0, pH 6.8), but is released very slowly at a low pH (e.g., pH 1.2, pH 2.0) because of the gelation.
  • This problem significantly imparts undesired effects on the dissolution rate and bioavailability of formulation because the formulation is first exposed to the acidic gastric juice having a low pH value when orally administered.
  • the combination formulation of the present invention separates the first discrete part comprising amlodipine and rosuvastatin from the second discrete part comprising losartan, thereby reducing the contact area of losartan.
  • the gelation of losartan can be prevented under a low pH condition and thus exhibit improved stability and dissolution rate of amlodipine, rosuvastatin and losartan.
  • the present invention also provides a fixed-dose combination formulation for the prevention or treatment of a cardiovascular disorder, comprising: (1) a first discrete part comprising amlodipine or a pharmaceutically acceptable salt thereof, rosuvastatin or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable additive; and (2) a second discrete part comprising losartan or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable additive, wherein said discrete parts are physically separated from each other.
  • the amount of amlodipine or a pharmaceutically acceptable salt thereof, as converted to amlodipine free base form is 5 to 10 mg. In one embodiment of the fixed-dose combination formulation, the amount of rosuvastatin or a pharmaceutically acceptable salt thereof, as converted to rosuvastatin free acid form, is 10 to 20 mg. Also, in one embodiment of the fixed-dose combination formulation, the amount of losartan or a pharmaceutically acceptable salt thereof, as converted to losartan free base form, is 45 to 100 mg.
  • the present; invention provides a method for preparing a pharmaceutical combination formulation for the prevention or treatment of a cardiovascular disorder, comprising: a) admixing amlodipine or a pharmaceutically acceptable salt thereof, rosuvastatin or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable additive; b) admixing losartan or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable salt thereof; and c) loading a discrete part prepared in Step a) and a discrete part prepared in Step b) into a formulation, wherein said discrete parts are physically separated from each other.
  • Step b) further comprises a granulizing step, and in Step c) the discrete part obtained in Step a) and the granules obtained in Step b) are tableted to obtain a bilayer tablet.
  • the cardiovascular disorder is selected from the group consisting of angina pectoris, hypertension, arteriospasm, cardiac arrhythmia, cardiomegaly, cerebral infarction, congestive heart failure and myocardial infarction, but not limited thereto.
  • amlodipine camsylate, rosuvastatin calcium, lactose hydrate, micro-crystalline cellulose and crospovidone were admixed, sieved through a 30 mesh screen, added with magnesium stearate and finally admixed in a mixer to obtain a discrete part comprising amlodipine and rosuvastatin - , ⁇
  • losartan potassium, micro-crystalline cellulose, hydroxypropyl cellulose and crospovidone were admixed, and sieved through a 30 mesh screen.
  • the sieved powder was pressed using a roller compactor ( WP200, Alexanderwerk) at a minimum compaction force of 20 kN with a roll speed of from 2 to 10 rpm to form granules in the form of flakes.
  • Granules thus obtained were pulverized by using a Fitz Mill (BAS 06, Fitzpatrick, USA), sieved through a 20 mesh screen, added with magnesium stearate and finally admixed in a mixer to obtain a discrete part comprising losartan.
  • the discrete parts were formulated into a combination bilayer tablet comprising the discrete part comprising amlodipine and rosuvastatin (first layer, upper layer) and the discrete part comprising losartan (second layer, lower layer) by using a tablet press (Kilian Synthesis 700, Germany).
  • Comparative Example 1 Preparation of single-layer tablet by using dry direct tableting
  • amlodipine camsylate, rosuvastatin calcium, losartan potassium, lactose hydrate, micro-crystallirie cellulose and crospovidone and hydroxypropyl cellulose were admixed, sieved through a 30 mesh screen, added with magnesium stearate and finally admixed in a mixer.
  • the mixed powder was formulated to obtain a single-layer tablet.
  • amlodipine camsylate, rosuvastatin calcium, lactose hydrate, micro-crystalline cellulose, and crospovidone were admixed, sieved through a 30 mesh screen, added with magnesium stearate and finally admixed in a mixer to obtain a discrete part comprising amlodipine and rosuvastatin:
  • losartan potassium, micro-crystalline cellulose, hydroxypropyl cellulose and crospovidone were admixed, sieved through a 30 mesh screen, added with magnesium stearate and finally admixed in a mixer to obtain a discrete part comprising losartan.
  • the discrete parts were formulated into a combination bilayer tablet comprising the discrete part comprising amlodipine and rosuvastatin (first -layer, upper layer) and the discrete part comprising losartan (second layer, lower layer) by using a tablet press.
  • Example 1 The procedure of Example 1 was repeated except for changing the ratio of lactose and cellulose in accordance with the ingredients as described in Table 4 below to obtain a combination bilayer tablet.
  • Ratio of lactose hydrate in the first layer 0% 36% 53%
  • Discrete part Losartan potassium 100.0 , . l o.o 100.0 comprising (Losartan, 91.6 mg)
  • Comparative Example 6 Preparation of combination bilayer tablet having different combination of active ingredients in the discrete part The procedure of Example 1 was repeated except for employing the ingredients as described in Table 5 below to obtain a combination bilayer tablet which comprises amlodipine and losartan in the first discrete part and rosuvastatin in the second discrete part.
  • Comparative Example 7 Preparation of combination bilayer tablet having different combination of active ingredients in the discrete part The procedure of Example 1 was repeated except for employing the ingredients as described in Table 6 below to obtain a combination bilayer tablet which comprises amlodipine in the first discrete part and losartan and rosuvastatin in the second discrete part.
  • Ratio of lactose hydrate in the first layer 28% 22% 36%
  • Discrete part Losartan potassium 50.0 50.0 50.0 comprising (Losartan, 45.8 mg)
  • Ratio of lactose hydrate in the first layer 0% 39% 56%
  • Discrete part Losartan potassium 50.0 50.0 ' 50.0 comprising (Losartan, 45.8 mg)
  • Example 1 Tablets prepared in Example 1 and Comparative Example 1 were each subjected to a drug dissolution test under the following conditions.
  • Dissolution media artificial gastric juice 900 mL (pH 1.2)
  • Dissolution media were taken 5, 10, 15, 30, 45, 60, 90 and 120 minutes after the test was commenced.
  • the paddle speed was raised from 50 rpm to 150 rpm, and after 30 minutes, i.e., 150 minutes after the test was commenced, dissolution media was taken for final analysis.
  • Dissolution rate of 80% or greater after 30 minutes (amlodipine, rosuvastatin)
  • the results of the dissolution test are shown in Figs. 2 to 4.
  • the bilayer tablet of Example 1 in which the discrete part comprising amlodipine and rosuvastatin and the discrete part comprising losartan are physically separated from each other exhibited a high dissolution rate as compared with the single layer tablet of Comparative Example 1 prepared by dry direct tableting.
  • the bilayer tablet of Example 1 showed a good dissolution profile of amlodipine and rosuvastatin, while satisfying the test criterion.
  • the bilayer tablet of Example 1 showed a significantly high dissolution rate of losartan compared with the single layer tablet of Comparative Example 1 which had dissolution rate of 40% or lower after 60 minutes.
  • the above results show that the gelation of losartan slows down the dissolution of amlodipine or rosuvastatin when losartan is present with amlodipine or rosuvastatin in the same layer.
  • the bilayer tablet of Example 1 prepared by compaction granulation and the bilayer tablet of Comparative Example 2 prepared by simple mixing followed by dry direct tableting were each subjected to a dissolution test by using the same conditions as described in Experimental Example 1 to evaluate dissolution rate of amlodipine, rosuvastatin and losartan.
  • the results are shown in Figs. 5 to 7.
  • the bilayer tablet of Example 1 which was prepared by using a roller compactor and the bilayer tablet of Comparative Example 2 which was prepared without using a roller compactor did not show much difference in dissolution rate of losartan.
  • the bilayer tablet of Comparative Example 2 which was prepared by simple mixing and dry direct tableting without using roller compactor exhibited a large deviation in dissolution, and a relatively low dissolution rate. Also, the bilayer tablet of Comparative Example 2 did not satisfy the test criterion (dissolution rate of 80% or greater after 30 minutes) in terms of amlodipine and rosuvastatin. Moreover, the losartan layer of Comparative Example 2 which was prepared without going through compaction granulation process, suffered from low productivity due to a problem associated with capping of the tablet. On the other hand, the bilayer tablet of Example 1 prepared by using a roller compactor showed an excellent dissolution rate of amlodipine and rosuvastatin, and also satisfied the test criterion.
  • the bilayer tablet of Example 1 which comprises the amlodipine-rosuvastatin layer and the losartan layer exhibited a fast and high dissolution rate, and showed a good dissolution profile of amlodipine and rosuvastatin by meeting the test criterion.
  • the bilayer tablet of Comparative Example 6 having the amlodipine-Iosartan layer and the rosuvastatin layer and the bilayer tablet of Comparative Example 7 having the amlodipine layer and the losartan-rosuvastatin layer failed to pass the test criterion in terms of dissolution rate of all three ingredients.
  • Test time initial, 1, 2, 4 and 6 months
  • Analysis target amlodipine, rosuvastatin and losartan
  • the tablets of Examples 1 to 3 exhibited high stability under accelerated light and heat conditions, while producing a very small amount of amlodipine-, rosuvastatin- and losartan-related substances.
  • the tablet obtained in Comparative Example 1 which was prepared by simple mixing of three ingredient followed by direct-compaction, produced related substances at least 5 to 10 times greater than the tablets obtained in Examples 1 to 3. This result indicates that tablets prepared by simple mixing have poor stability under accelerated light and heat conditions.
  • Comparative Example 6 shows that the bilayer tablet having the amlodipine-losartan layer and the rosuvastatin layer exhibits poor stability under accelerated light and heat conditions.
  • Comparative Example 7 shows that the bilayer tablet having the amlodipine layer and the losartan-rosuvastatin layer also exhibits poor stability under accelerated light and heat conditions.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Disclosed is a pharmaceutical combination formulation comprising a first discrete part containing amlodipine and rosuvastatin and a second discrete part containing losartan, which exhibits improved dissolution rate and stability. The inventive combination formulation comprising amlodipine, losartan and rosuvastatin having different action mechanisms from one another can be effectively used to prevent or treat a cardiovascular disorder. Designed to minimize an interaction among active ingredients, the pharmaceutical combination formulation exhibits excellent storage stability and dissolution rates of amlodipine, losartan and rosuvastatin, and thus can be useful in pharmaceutical industries.

Description

DESCRIPTION
PHARMACEUTICAL COMBINATION FORMULATION COMPRISING AMLODIPINE, LOSARTAN AND ROSUVASTATIN
FIELD OF THE INVENTION
The present invention relates to a pharmaceutical combination formulation comprising amlodipine, losartan and rosuvastatin. More specifically, it relates to a pharmaceutical combination formulation comprising a first discrete part containing amlodipine and rosuvastatin and a second discrete part containing losartan, which exhibits improved dissolution rate and stability.
BACKGROUND OF THE INVENTION
About 90 to 95% of hypertension cases are categorized as primary hypertension which means high blood pressure with no obvious underlying medical cause. The exact cause of primary hypertension is unknown, but a number of factors including increase in cardiac output (the volume of blood being pumped out by the heart) or peripheral resistance are believed to contribute to the onset of the disease. Risk factors that are related to hypertension include psychological and environmental factors such as drinking, smoking, aging, lack of exercise, obesity, too much salt in the diet, stress and the like. Genetically, when both parents have hypertension, the offspring has an 80% chance of having hypertension; if one of the parents has hypertension, the offspring has a 25 to 50% chance of having hypertension.
The ultimate goal in the treatment of hypertension is to maintain an optimal blood pressure to minimize tissue damage caused by hypertension. Thus, adopting a preventative lifestyle is as important as taking a medication. It is a goal to keep blood pressure less than 140/90 mmHg for patients with hypertension, and less than 130/80 mml lg for hypertensive patients with diabetic or nephritis complications.
If hypertension is treated, it may reduce mortality caused by stroke and cardiovascular disorders. When patients with hypertension are properly treated, it is estimated that risks of experiencing stroke, myocardial infarction and heart failure are lowered by about 35-40%, 20-25% and more than 50%, respectively. Lowering systolic blood pressure by 5 mmHg reduces all-cause mortality by 7% on a population basis, while mortality for coronary heart disease and stroke can be reduced by 9% and 14%, respectively. Also, blood pressure is closely related to Alzheimer's disease and, thus, blood pressure management may reduce the risk of Alzheimer's disease.
Since avoiding risk factors for cardiovascular complications is very important to hypertensive patients as explained above, continuous blood pressure management is critical to those patients. Moreover, since it is required to take medications for a long period of time in the treatment of hypertension, a combination of drugs of different mechanisms has an advantage over individual drugs in terms of preventive and therapeutic effect. Also, a combination therapy reduces doses of individual drugs, thereby reducing side effects which may occur due to long-term administration of individual drugs.
In general, medications that are often used in the treatment■ of hypertension are categorized into, according to their mechanism of action, diuretics, sympatholytic agents and vasodilators; and vasodilators are further categorized in accordance with their mechanism of action, as follows: angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers and calcium channel blockers.
Meanwhile, hyperlipidemia is a disorder in which an excessively high level of lipids in the blood cause a buildup of plaque on the walls of the arteries, followed by inflammation and, ultimately, cardiovascular disorders. In recent years, an abnormal amount of lipids in the blood is defined as dyslipidemia.
In the treatment of hyperlipidemia, non-drug therapies such as lifestyle changes
(including physical exercise and diets) and maintaining ideal body weight;, may be used in conjunction with medication. Statin-based drugs are often used, and these drugs act as an HMG-CoA reductase inhibitor which has an ability to inhibit cholesterol synthesis and thereby to cause significant reduction in plasma LDL-cholesterol levels, and also result in partial reduction in triglycerides levels. Amlodipine is a generic name for
3-ethyl-5-methyl-2-(2-aminoethoxy-methyl)-4-^
ine dicarboxylate, and, in particular, amlodipine besylate is commercially available under the trade name Novasc®. Amlodipine camsylate, as disclosed in Korean Patent No. 452491, shows superior solubility and stability to amlodipine besylate, and is currently available under the trade name Amodipin®. Amlodipine blocks calcium channel, and is useful in the treatment of cardiovascular disorders such as angina, hypertension and congestive heart failure.
Losartan is a generic name for
2-butyl-4-chloro-l-[2,-(lH-tetrazol-5-yl)[l,l'-biphenyl]-4-yl]methyl]-lH-imidazol-5-methan^ as disclosed in U.S. Pat. Nos. 5,608,075, 5,138,069 and 5,153,197. ; Currently losartan potassium is commercially available under the trade name Cozaar®, By blocking the interaction of angiotensin II and its receptor, losartan is mainly used for treating hypertension, heart failure, ischemic peripheral circulatory disorder, myocardial ischemia (angina pectoris), diabetic neuropathy and glaucoma, and also for preventing the progression of post-myocardial infarction heart failure.
A combination formulation of amlodipine and losartan that have different mechanism of action from each other has an advantage over the individual drugs in terms of preventive and therapeutic effect. In addition, such formulation reduces doses of the individual drugs, thereby decreasing side effects which may occur due to a long-term administration of the individual drugs. The combination formulation is disclosed in Korean Patent Nos. 1 160151, 1232296, etc., and currently sold under the trade name Amosartan .
Figure imgf000004_0001
effective in the treatment of hypercholesterolemia, hyperlipoproteinemia or atherosclerosis.
The co-occurrence rate of hypertension and hyperlipidemia is approximately 49%, and co-administration of Amosartan® and statin-based drugs takes up about 30% in the drug treatment of cardiovascular disorders.
In clinical research, there is a growing need for a combination formulation including
3 . ■■■■ amlodipine, losartan and rosuvastatin having different mechanisms for more effective treatment of cardiovascular disorders. However, it is difficult to commercialize such formulation due to complexity in designing and a possibility of deterioration in dissolution and stability due to interaction among the active ingredients.
Leading to the present invention, the present inventors have conducted intensive research to redress the problems of the conventional formulations, and found that dissolution rate and stability of the active ingredients varied depending on the structure of a bilayer tablet and the manufacturing method thereof, and thus accomplished a pharmaceutical combination formulation comprising amlodipine, losartan and rosuvastatin having improved dissolution rate and stability.
SUMMARY OF THE INVENTION
Therefore, it is an object of the present invention to provide a pharmaceutical combination formulation for the treatment of a cardiovascular disorder comprising amlodipine, losartan and rosuvastatin, having different action mechanisms from one another, which exhibits excellent dissolution and stability properties.
In accordance with one aspect of the present invention, there is provided a pharmaceutical combination formulation for the prevention or treatment of a cardiovascular disorder, comprising: (1) a first discrete part comprising amlodipine or a pharmaceutically acceptable salt thereof, rosuvastatin or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable additive; and (2) a second discrete part comprising losartan or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable additive, wherein said discrete parts are physically separated from each other.
The pharmaceutical combination formulation comprising amlodipine, losartan and rosuvastatin can be effectively used to prevent or treat a cardiovascular disorder. Designed to minimize an interaction among active ingredients, the pharmaceutical combination formulation exhibits excellent storage stability and dissolution rates of amlodipine, losartan and rosuvastatin, and thus can be useful in pharmaceutical industries. BRIEF DESCRIPTION OF THE DRAWING
The above and other objects and features of the present invention will be more clearly understood from the following detailed description in conjunction with the accompanying drawings, in which:
Fig. 1 is a schematic view showing a bilayer tablet according to one embodiment of the present invention.
Fig. 2 is a graph showing dissolution rate of amlodipine in the formulations of Example 1 and Comparative Example 1.
Fig. 3 is a graph showing dissolution rate of rosuvastatin in the formulations of Example 1 and Comparative Example 1.
Fig. 4 is a graph showing dissolution rate of losartan in the formulations of Example 1 and Comparative Example 1.
Fig. 5 is a graph showing dissolution rate of amlodipine in the formulations of Example 1 and Comparative Example 2.
Fig. 6 is a graph showing dissolution rate of rosuvastatin in the formulations of Example 1 and Comparative Example 2.
Fig. 7 is a graph showing dissolution rate of losartan in the formulations of Example 1 and Comparative Example 2.
Fig. 8 is a graph showing dissolution rate of amlodipine in the formulations of Examples 1 to 3 and Comparative Examples 3 to 5.
Fig. 9 is a graph showing dissolution rate of rosuvastatin in the formulations of Examples 1 to 3 and Comparative Examples 3 to 5. ?
Fig. 10 is a graph showing dissolution rate of losartan in the formulations of Examples 1 to 3 and Comparative Examples 3 to 5.
Fig. 1 1 is a graph showing dissolution rate of amlodipine in the formulations of Example 1 and Comparative Examples 6 and 7.
Fig. 12 is a graph showing dissolution rate of rosuvastatin in the formulations of Example 1 and Comparative Examples 6 and 7.
Fig. 13 is a graph showing dissolution rate of losartan in the formulations of Example 1 and Comparative Examples 6 and 7.
Fig. 14 is a graph showing dissolution rate of amlodipine in. the formulations of Examples 4 to 6 and Comparative Examples 8 to 10.
Fig. 15 is a graph showing dissolution rate of rosuvastatin in the formulations of Examples 4 to 6 and Comparative Examples 8 to 10.
Fig. 16 is a graph showing dissolution rate of losartan in the formulations of Examples 4 to 6 and Comparative Examples 8 to 10.
DETAILED DESCRIPTION OF THE INVENTION
The present invention provides a pharmaceutical combination formulation for the prevention or treatment of a cardiovascular disorder, comprising: (1) a first discrete part comprising amlodipine or a pharmaceutically acceptable salt thereof, rosuvastatin or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable additive; and (2) a second discrete part comprising losartan or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable additive, wherein said discrete parts are physically separated from each other.
The combination formulation according to the present invention comprises the first and the second discrete parts in which said discrete parts are physically separated, i.e., amlodipine and losartan are separately contained. Thus, an interaction between amlodipine and losartan is prevented, thereby exhibiting improved stability.
In one embodiment of the present invention, the first discrete part and the second discrete part in the combination formulation may be a first layer and a second layer, respectively. In other words, the combination formulation may be in the form of a bilayer tablet comprising: (1) a first layer comprising amlodipine or a pharmaceutically acceptable salt thereof, rosuvastatin or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable additive; and (2) a second layer comprising losartan or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable additive (see Fig. 1). Besides a bilayer tablet, in another embodiment of the present invention, the combination formulation may be prepared in various forms where a first discrete part and a second discrete part are physically separated from each other (for example, core-shell structure).
The combination formulation of the present invention comprises amlodipine or a pharmaceutically acceptable salt thereof in the first discrete part (or the first layer). The pharmaceutically acceptable salt of amlodipine employed in the present invention may be prepared by using an acid containing a pharmaceutically acceptable anion which can form a non-toxic acid addition salt, e.g., hydrogen chloride, hydrogen bromide, sulfate, phosphate, acetate, malate, furmarate, lactate, tartrate, citrate, gluconate, besylate and camsylate, but are not limited thereto. Preferably, the pharmaceutically acceptable salt of amlodipine is amlodipine besylate and camsylate, more preferably camsylate. Also, amlodipine of . the present invention includes a racemic mixture and (S)-amlodipine. Amlodipine or a pharmaceutically acceptable salt thereof may be administered at a daily dose of from 5 to 10 mg.
The combination formulation of the present invention comprises rosuvastatin or a pharmaceutically acceptable salt thereof in the first discrete part (or the first layer). Examples of the pharmaceutically acceptable salt of rosuvastatin include inorganic salts having polycation, preferably rosuvastatin calcium, but are not limited thereto. Rosuvastatin or a pharmaceutically acceptable salt thereof may be administered at a daily dose of from 10 to 20 mg.
The combination formulation of the present invention comprises losartan or a pharmaceutically acceptable salt thereof in the second discrete part (or the second layer). Examples of the pharmaceutically acceptable salt of losartan include losartan potassium, but are not limited thereto. Losartan or a pharmaceutically acceptable salt thereof may be administered at a daily dose of from 45 to 100 mg.
In the combination formulation of the present invention, amlodipine or a pharmaceutically acceptable salt thereof, rosuvastatin or a pharmaceutically acceptable salt thereof and losartan or a pharmaceutically acceptable salt thereof may be admixed in a weight ratio of 1 : 1-4 : 10-20, but not limited thereto.
In the present invention, the first discrete part (or the first layer) arid the second discrete part (or the second layer) of the combination formulation may further comprise a pharmaceutically acceptable additive, e.g., a pharmaceutically acceptable;. carrier or excipient. Examples of the pharmaceutically acceptable carrier or excipient include lactose (lactose hydrate), micro-crystalline cellulose, mannitol, sodium citrate, ΰ3ΐϋίμπι citrate, calcium phosphate, glycine and starch, a disintegrant (e.g., crospovidone, copovidone, sodium starch glycolate, croscarmellose sodium, and combination silicates) and a binder (e.g. , polyvinylpyrrolidone, hydroxypropyl methyl cellulose (HPMC), hydroxypropyl cellulose (HPC), sucrose, gelatin and acacia gum.
In one embodiment, the combination formulation of the present invention comprises lactose hydrate and micro-crystalline cellulose in the first discrete part (or the first layer) as additives. The lactose hydrate may be comprised in an amount of from 20 to 40 wt% based on the total weight of the first discrete part (or the first layer). The micro-crystalline cellulose may be comprised in an amount of from 50 to 70 wt% based on the total weight of the first discrete part (or the first layer). In another embodiment, the lactose hydrate and micro-crystalline cellulose may be employed in a ratio of 1 : 1.5 to 1 :3.
When the lactose hydrate is employed in said range, the lactose hydrate may form hydrophilic channels which promote dissolution of active ingredients, thereby allowing a fast dissolution. A fast dissolution profile cannot be obtained if the amount falls below said range, and if the amount exceeds said range, time required for complete dissolution of the lactose hydrate is extended and thereby slowing down the dissolution of active ingredients. In case of micro-crystalline cellulose, the tableting process becomes easy if the micro-crystalline cellulose is employed in said range. However, an amount smaller than said range may cause some difficulties during the tableting process, whereas an excessive amount may lead to an excessively large size of formulation.
Accordingly, dissolution rates of amlodipine, rosuvastatin and losartan may be improved significantly by employing the lactose hydrate and micro-crystalline cellulose in said range.
In one embodiment, the second discrete part (or the second layer) of the inventive combination formulation may be prepared in a conventional manner, e.g., compaction granulation followed by tableting. In another embodiment, the second discrete part is in the form of granules prepared by a dry roller compaction process. According to the experimental results of the present invention, a combination formulation exhibited improved dissolution rate of amlodipine, rosuvastatin and losartan, as well as excellent dissolution profiles of amlodipine and rosuvastatin when the combination formulation was prepared by tableting a simply mixed first discrete part and a second discrete part prepared by compaction granulation.
A problem of gelation of losartan occurs when a combination formulation is prepared by simply mixing amlodipine, rosuvastatin and losartan. Losartan readily dissolves in purified water and is easily released at a relatively high pH (e.g., pH 4.0, pH 6.8), but is released very slowly at a low pH (e.g., pH 1.2, pH 2.0) because of the gelation. This problem significantly imparts undesired effects on the dissolution rate and bioavailability of formulation because the formulation is first exposed to the acidic gastric juice having a low pH value when orally administered. As the gelation of losartan progresses in the formulation, amlodipine and rosuvastatin are trapped within the losartan gel and dissolve poorly, which is demonstrated in Comparative Example 1. The dissolution result of a single layer tablet of Comparative Example 1 prepared by simply mixing said three ingredients was significantly lower than "80% dissolution at the time of 30 minutes in pH 1.2."
In comparison, the combination formulation of the present invention separates the first discrete part comprising amlodipine and rosuvastatin from the second discrete part comprising losartan, thereby reducing the contact area of losartan. As a result, the gelation of losartan can be prevented under a low pH condition and thus exhibit improved stability and dissolution rate of amlodipine, rosuvastatin and losartan.
Meanwhile, the present invention also provides a fixed-dose combination formulation for the prevention or treatment of a cardiovascular disorder, comprising: (1) a first discrete part comprising amlodipine or a pharmaceutically acceptable salt thereof, rosuvastatin or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable additive; and (2) a second discrete part comprising losartan or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable additive, wherein said discrete parts are physically separated from each other.
In one embodiment of the fixed-dose combination formulation, the amount of amlodipine or a pharmaceutically acceptable salt thereof, as converted to amlodipine free base form, is 5 to 10 mg. In one embodiment of the fixed-dose combination formulation, the amount of rosuvastatin or a pharmaceutically acceptable salt thereof, as converted to rosuvastatin free acid form, is 10 to 20 mg. Also, in one embodiment of the fixed-dose combination formulation, the amount of losartan or a pharmaceutically acceptable salt thereof, as converted to losartan free base form, is 45 to 100 mg.
Moreover, in accordance with another aspect thereof, the present; invention provides a method for preparing a pharmaceutical combination formulation for the prevention or treatment of a cardiovascular disorder, comprising: a) admixing amlodipine or a pharmaceutically acceptable salt thereof, rosuvastatin or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable additive; b) admixing losartan or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable salt thereof; and c) loading a discrete part prepared in Step a) and a discrete part prepared in Step b) into a formulation, wherein said discrete parts are physically separated from each other.
In one embodiment, Step b) further comprises a granulizing step, and in Step c) the discrete part obtained in Step a) and the granules obtained in Step b) are tableted to obtain a bilayer tablet.
In the present invention, the cardiovascular disorder is selected from the group consisting of angina pectoris, hypertension, arteriospasm, cardiac arrhythmia, cardiomegaly, cerebral infarction, congestive heart failure and myocardial infarction, but not limited thereto.
Hereinafter, the present invention is described more specifically by following examples. However, these examples are provided only for illustration purposes, and the present invention is not limited thereto.
Examples 1 to 3: Preparation of combination bilayer tablet by using compaction granulation
In accordance with the ingredients as described in Table 1 below, amlodipine camsylate, rosuvastatin calcium, lactose hydrate, micro-crystalline cellulose and crospovidone were admixed, sieved through a 30 mesh screen, added with magnesium stearate and finally admixed in a mixer to obtain a discrete part comprising amlodipine and rosuvastatin - ,·
Meanwhile, losartan potassium, micro-crystalline cellulose, hydroxypropyl cellulose and crospovidone were admixed, and sieved through a 30 mesh screen. Then, the sieved powder was pressed using a roller compactor ( WP200, Alexanderwerk) at a minimum compaction force of 20 kN with a roll speed of from 2 to 10 rpm to form granules in the form of flakes. Granules thus obtained were pulverized by using a Fitz Mill (BAS 06, Fitzpatrick, USA), sieved through a 20 mesh screen, added with magnesium stearate and finally admixed in a mixer to obtain a discrete part comprising losartan.
Subsequently, the discrete parts were formulated into a combination bilayer tablet comprising the discrete part comprising amlodipine and rosuvastatin (first layer, upper layer) and the discrete part comprising losartan (second layer, lower layer) by using a tablet press (Kilian Synthesis 700, Germany).
[Table 1]
Figure imgf000012_0001
Comparative Example 1: Preparation of single-layer tablet by using dry direct tableting
In accordance with the ingredients as described in Table 2 below, amlodipine camsylate, rosuvastatin calcium, losartan potassium, lactose hydrate, micro-crystallirie cellulose and crospovidone and hydroxypropyl cellulose were admixed, sieved through a 30 mesh screen, added with magnesium stearate and finally admixed in a mixer. The mixed powder was formulated to obtain a single-layer tablet.
[Table 2]
Figure imgf000013_0001
Comparative Example 2: Preparation of bilayer tablet using dry direct tableting
In accordance with the ingredients as described in Table 3 below, amlodipine camsylate, rosuvastatin calcium, lactose hydrate, micro-crystalline cellulose, and crospovidone were admixed, sieved through a 30 mesh screen, added with magnesium stearate and finally admixed in a mixer to obtain a discrete part comprising amlodipine and rosuvastatin:
Meanwhile, losartan potassium, micro-crystalline cellulose, hydroxypropyl cellulose and crospovidone were admixed, sieved through a 30 mesh screen, added with magnesium stearate and finally admixed in a mixer to obtain a discrete part comprising losartan.
Subsequently, the discrete parts were formulated into a combination bilayer tablet comprising the discrete part comprising amlodipine and rosuvastatin (first -layer, upper layer) and the discrete part comprising losartan (second layer, lower layer) by using a tablet press.
[Table 3]
Figure imgf000014_0001
Comparative Examples 3 to 5: Preparation of bilayer tablet by using compaction granulation
The procedure of Example 1 was repeated except for changing the ratio of lactose and cellulose in accordance with the ingredients as described in Table 4 below to obtain a combination bilayer tablet.
[Table 4]
Component Ingredient (mg) Comparative Comparative Comparative
Example 3 Example 4 Example 5
Discrete part Amlodipine camsylate 7.8 7.8 7.8 comprising (Amlodipine, 5 mg)
amlodipine + Rosuvastatin calcium 20.8 20.8 b . 20.8 rosuvastatin (Rosuvastatin, 20 mg) Lactose hydrate - 52.0 104.0
Micro-crystalline cellulose 104.0 52.0 52.0
Crospovidone 10.0 10.0 10.0
Magnesium stearate 2.0 2.0 2.0
Ratio of lactose hydrate in the first layer 0% 36% 53%
Ratio of micro-crystalline cellulose 72% 36% i: 26%
in the first layer
Discrete part Losartan potassium 100.0 , . l o.o 100.0 comprising (Losartan, 91.6 mg)
losartan Micro-crystalline cellulose 182.0 182.0 182.0
Crospovidone 15.0 15.0 15.0
Hydroxypropyl cellulose 4.0 4.0 4.0
Magnesium stearate 3.0 3.0 3.0
Comparative Example 6: Preparation of combination bilayer tablet having different combination of active ingredients in the discrete part The procedure of Example 1 was repeated except for employing the ingredients as described in Table 5 below to obtain a combination bilayer tablet which comprises amlodipine and losartan in the first discrete part and rosuvastatin in the second discrete part.
[Table 5]
Figure imgf000015_0001
Hydroxypropyl cellulose 4.0
Magnesium stearate 3.0 v
Comparative Example 7: Preparation of combination bilayer tablet having different combination of active ingredients in the discrete part The procedure of Example 1 was repeated except for employing the ingredients as described in Table 6 below to obtain a combination bilayer tablet which comprises amlodipine in the first discrete part and losartan and rosuvastatin in the second discrete part.
[Table 6]
Figure imgf000016_0001
Examples 4 to 6: Preparation of combination bilayer tablet having different amounts of active ingredients
In accordance with the ingredients as described in Table 7 below, combination bilayer tablets which have different amounts of active ingredients than Examples 1 to 3 were prepared. [Table 7] Component Ingredient (mg) Example 4 Example 5 ' Example 6
Discrete part Amlodipine camsylate 7.8 7.8 7.8 comprising (Amlodipine, 5 mg)
amlodipine + Rosuvastatin calcium 10.8 10.8 10.8 rosuvastatin (Rosuvastatin, 10
mg)
Lactose hydrate 52.0 52.0 104.0
Micro-crystalline cellulose 104.0 156.0 156.0
Crospovidone 10.0 10.0 10.0
Magnesium stearate 2.0 2.0 . 2.0
Ratio of lactose hydrate in the first layer 28% 22% 36%
Ratio of micro-crystalline cellulose 56% 65% 54%
in the first layer
Discrete part Losartan potassium 50.0 50.0 50.0 comprising (Losartan, 45.8 mg)
losartan Micro-crystalline cellulose 91.0 91.0 91.0
Crospovidone 7.5 7.5 7.5
Hydroxypropyl cellulose 2.0 2.0 2.0
Magnesium stearate 1.5 1.5 1.5
Comparative Examples 8 to 10: Preparation of combination bilayer tablet having different amounts of active ingredients
In accordance with the ingredients as described in Table 8 below; combination bilayer tablets were prepared by repeating the procedure of Example 1.
[Table 8]
Figure imgf000017_0001
Micro-crystalline cellulose 104.0 52.0 52.0
Crospovidone 10.0 10.0 10.0
Magnesium stearate 2.0 2.0 2.0
Ratio of lactose hydrate in the first layer 0% 39% 56%
Ratio of micro-crystalline cellulose 77% 39% 28%
in the first layer
Discrete part Losartan potassium 50.0 50.0 ' 50.0 comprising (Losartan, 45.8 mg)
losartan Micro-crystalline cellulose 91.0 91.0 91.0
Crospovidone 7.5 7.5 7.5
Hydroxypropyl cellulose 2.0 2.0 2.0
Magnesium stearate 1.5 1 -5 1.5
Experimental Example 1: Dissolution test of single layer tablet and bilayer tablet
Tablets prepared in Example 1 and Comparative Example 1 were each subjected to a drug dissolution test under the following conditions.
- Test conditions -
Dissolution media: artificial gastric juice 900 mL (pH 1.2)
Apparatus: USP paddle method, 50 rpm
Temperature: 37°C
Sampling: Dissolution media were taken 5, 10, 15, 30, 45, 60, 90 and 120 minutes after the test was commenced. The paddle speed was raised from 50 rpm to 150 rpm, and after 30 minutes, i.e., 150 minutes after the test was commenced, dissolution media was taken for final analysis.
- Analytical conditions -
Column: stainless steel column (inner diameter: about 4.6 mm, length: 15 cm) packed with 3 μπι of octadecylsilylated silica gel for liquid chromatography
Mobile phase: 6 mM sodium hexanesulfonate monohydrate/0.05% v/y phosphoric acid : acetonitrile (60:40,v/v)
(6 mM sodium hexanesulfonate monohydrate/0.05% v/v phosphoric acid : 1.24 g of sodium 1-hexanesulfonate monohydrate was added to an 1 L flask, and 0.5 mL of phosphoric acid was carefully added. Distilled water was added and thoroughly stirred.)
Detector: ultraviolet spectrophotometer (absorbance at 254 nm)
Flow rate: 1.3 mL/min
Injection volume: 10 μΐ,
Column temperature: 45°C
- Test criterion -
Dissolution rate of 80% or greater after 30 minutes (amlodipine, rosuvastatin)
The results of the dissolution test are shown in Figs. 2 to 4. As shown in Figs. 2 and 3, the bilayer tablet of Example 1 in which the discrete part comprising amlodipine and rosuvastatin and the discrete part comprising losartan are physically separated from each other exhibited a high dissolution rate as compared with the single layer tablet of Comparative Example 1 prepared by dry direct tableting. Also, unlike the single layer tablet of Comparative Example 1 , the bilayer tablet of Example 1 showed a good dissolution profile of amlodipine and rosuvastatin, while satisfying the test criterion.
Moreover, as shown in Fig. 4, the bilayer tablet of Example 1 showed a significantly high dissolution rate of losartan compared with the single layer tablet of Comparative Example 1 which had dissolution rate of 40% or lower after 60 minutes. The above results show that the gelation of losartan slows down the dissolution of amlodipine or rosuvastatin when losartan is present with amlodipine or rosuvastatin in the same layer.
Experimental Example 2: Dissolution test of bilayer- tablet with compaction-granulated losartan part and bilayer tablet prepared by dry direct tableting
The bilayer tablet of Example 1 prepared by compaction granulation and the bilayer tablet of Comparative Example 2 prepared by simple mixing followed by dry direct tableting were each subjected to a dissolution test by using the same conditions as described in Experimental Example 1 to evaluate dissolution rate of amlodipine, rosuvastatin and losartan. The results are shown in Figs. 5 to 7. As shown in Fig. 7, the bilayer tablet of Example 1 which was prepared by using a roller compactor and the bilayer tablet of Comparative Example 2 which was prepared without using a roller compactor did not show much difference in dissolution rate of losartan.
However, as shown in Figs. 5 and 6, the bilayer tablet of Comparative Example 2 which was prepared by simple mixing and dry direct tableting without using roller compactor exhibited a large deviation in dissolution, and a relatively low dissolution rate. Also, the bilayer tablet of Comparative Example 2 did not satisfy the test criterion (dissolution rate of 80% or greater after 30 minutes) in terms of amlodipine and rosuvastatin. Moreover, the losartan layer of Comparative Example 2 which was prepared without going through compaction granulation process, suffered from low productivity due to a problem associated with capping of the tablet. On the other hand, the bilayer tablet of Example 1 prepared by using a roller compactor showed an excellent dissolution rate of amlodipine and rosuvastatin, and also satisfied the test criterion.
The above results demonstrate that the roller compaction process of losartan granules not only affects dissolution profiles of three active ingredients, but also can affect the productivity of tableting process.
Experimental Example 3: Changes in dissolution rate depending on the ratio of additives in amlodipine-rosuvastatin layer A dissolution test was performed by using the same conditions as described in
Experimental Example 1 on the bilayer tablets of Examples 1 to 3 and Comparative Examples 3 to 5 to evaluate dissolution rate of amlodipine, rosuvastatin and losartan. The results are shown in Figs. 8 to 10.
As shown in Fig. 10, the bilayer tablets of Examples 1 to 3 and Comparative Examples 3 to 5 did not show much difference in dissolution rate of losartan.
However, as shown in Figs. 8 and 9, the bilayer tablets of Examples 1 to 3 exhibited good dissolution profiles that satisfied the test criterion, whereas the bilayer tablets of Comparative Examples 3 to 5 failed to satisfy the test criterion.
The test results suggest that it is preferable, in terms of dissolution rate, to employ lactose hydrate and micro-crystalline cellulose in weight ratios of 20 to 40 wt% and 50 to 70 wt%, respectively, in the amlodipine-rosuvastain layer. Experimental Example 4: Dissolution test of Comparative Examples 6 (tablet comprising amlodipine-Iosartan layer and rosuvastatin layer) and 7 (tablet comprising amlodipine layer and losartan-rosuvastatin layer)
A dissolution test was performed by using the same conditions as described in Experimental Example 1 on the bilayer tablet of Example 1 and the bilayer tablets of Comparative Examples 6 and 7 to evaluate dissolution rate of amlodipine, rosuvastatin and losartan. The results are shown in Figs. 11 to 13.
As shown in Figs. 1 1 to 13, the bilayer tablet of Example 1 which comprises the amlodipine-rosuvastatin layer and the losartan layer exhibited a fast and high dissolution rate, and showed a good dissolution profile of amlodipine and rosuvastatin by meeting the test criterion. In contrast, the bilayer tablet of Comparative Example 6 having the amlodipine-Iosartan layer and the rosuvastatin layer and the bilayer tablet of Comparative Example 7 having the amlodipine layer and the losartan-rosuvastatin layer failed to pass the test criterion in terms of dissolution rate of all three ingredients.
The above results demonstrate that it is preferable to prepare a bilayer tablet comprising the amlodipine-rosuvastatin layer and the losartan layer, because a delay in dissolution is expected due to the gelation of losartan when a bilayer tablet comprises an amlodipine-Iosartan layer and a rosuvastatin layer or an amlodipine layer and a losartan-rosuvastatin layer. Thus, the results also show that a separation mode of said three drugs is critical in terms of dissolution rate.
Experimental Example 5: Stability test under accelerated storage conditions
A stability test was performed for the tablets of Examples 1 to 3 under the following conditions to evaluate the stability of the tablets by analyzing the content change in amlodipine, rosuvastatin and losartan. The results are shown in Table 9.
-Accelerated storage test condition- Storage condition: stored in an HDPE bottle at 40°C, 75% RH
Test time: initial, 1, 2, 4 and 6 months Analysis target: amlodipine, rosuvastatin and losartan
- Analytical conditions -
Column: stainless steel column (inner diameter: about 4.6 mm, length: 15 cm) packed with 3 μηι of octadecylsilylated silica gel for liquid chromatography
Mobile phase: 6 mM sodium hexanesulfonate monohydrate/0.05%(v/v) phosphoric acid : acetonitrile (6:4, v/v)
Detector: ultraviolet spectrophotometer (absorbance at 254 nm)
Flow rate: 1.3 mL/min
Injection volume: 10 μΐ,
Column temperature: 45°C
[Table 9]
Figure imgf000022_0001
As shown in Table 9 above, the bilayer tablets of Examples 1 to 3 exhibited insignificant changes in the content of amlodipine, rosuvastatin and losartan unde 6 month accelerated storage, thereby indicating exceptionally good storage stability.
Experimental Example 6: Stability test under accelerated light and heat conditions
A stability test was performed for the tablets prepared in Examples 1 to 3 and Comparative Examples 1 to 7 under the following conditions to analyze the changes in production rate of related substances of amlodipine, rosuvastatin and losartan under accelerated light and heat conditions. The results are shown in Table 10. - Accelerated test conditions (light stability)-
(1) Apparatus: Xe-3-HC (Q-Lab)
(2) Temperature and humidity: 25°C ± 2°C / 60% ± 5% RH :
(3) Light: 0.80 W/m2/nm, 18.44 hours
(1,200,000 lux, method according to ICH Guidelines)
(4) Sample: stored on a Petri dish
(5) Test time: initial and after the exposure
- Accelerated test condition (heat stability)-
(1) Temperature and humidity: 50°C ± 2°C
(2) Sample: stored in an HDPE bottle
(3) Test time: initial and after 28 days
- Analytical conditions -
Column: stainless steel column (inner diameter: about 4.6 mm, length: 25 cm) packed with 5 μπι of octadecylsilylated silica gel for liquid chromatography
Mobile phase: 6 mM sodium hexanesulfonate monohydrate7Q;i05.%(v/v) phosphoric acid : acetonitrile (6:4, v/v)
Detector: ultraviolet spectrophotometer (absorbance at 254 nm)
Flow rate: 1.0 mL/min
Injection volume: 10 μϋ
Column temperature: 45°C
[Table 10]
Figure imgf000024_0001
As shown in Table 10 above, the tablets of Examples 1 to 3 exhibited high stability under accelerated light and heat conditions, while producing a very small amount of amlodipine-, rosuvastatin- and losartan-related substances. On the other hand, the tablet obtained in Comparative Example 1 , which was prepared by simple mixing of three ingredient followed by direct-compaction, produced related substances at least 5 to 10 times greater than the tablets obtained in Examples 1 to 3. This result indicates that tablets prepared by simple mixing have poor stability under accelerated light and heat conditions.
Additionally, the tablets obtained in Comparative Examples 6 and 7 produced related substances as much as Comparative Example 1. The test result of Comparative Example 6 shows that the bilayer tablet having the amlodipine-losartan layer and the rosuvastatin layer exhibits poor stability under accelerated light and heat conditions. Similarly, the test result of Comparative Example 7 shows that the bilayer tablet having the amlodipine layer and the losartan-rosuvastatin layer also exhibits poor stability under accelerated light and heat conditions.
This result indicates that the bilayer tablet having the amlodipine-rosuvastatin layer and the losartan layer of Examples 1 to 3 have significantly improved stability.
Experimental Example 7: Stability test of bilayer tablets having different amounts of active ingredient
A stability test was performed for the tablets prepared in Examples 4 to 6 and Comparative Examples 8 to 10, which had different amounts of active ingredients, to evaluate dissolution rate of amlodipine, rosuvastatin and losartan. The results are shown in Figs. 14 to 16.
As shown in Figs. 14 to 16, the tablets of Examples 4 to 6, which contained 50 mg of losartan and 10 mg of rosuvastatin, exhibited similar dissolution profiles as those of Examples 1 to 3 and satisfied the test criterion.
On the other hand, the tablets of Comparative Examples 8 to 10 failed to pass the test criterion in terms of dissolution rates of amlodipine and rosuvastatin.
This result indicates that a tablet can maintain a good dissolution rate even if the amount of active ingredient changes, as long as the amlodipine-rosuvastatin layer contains the lactose hydrate in an amount of 20 to 40 wt%, and micro-crystalline cellulose in an amount of 50 to 70 wt%.

Claims

What is claimed is:
1. A pharmaceutical combination formulation, comprising:
(1) a first discrete part comprising amiodipine or a pharmaceutically acceptable salt thereof, rosuvastatin or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable additive; and
(2) a second discrete part comprising losartan or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable additive,
wherein said discrete parts are physically separated from each other.
2. The pharmaceutical combination formulation of claim 1, wherein the combination formulation is in the form of a bilayer tablet comprising:
(1) a first layer comprising amiodipine or a pharmaceutically acceptable salt thereof, rosuvastatin or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable additive; and
(2) a second layer comprising losartan or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable additive.
3. The pharmaceutical combination formulation of claim 1 , wherein the first discrete part comprises lactose hydrate and micro-crystalline cellulose as additives.
4. The pharmaceutical combination formulation of claim 3, wherein the lactose hydrate is comprised in an amount of 20 to 40 wt% based on the total weight of the first discrete part, and the micro-crystalline cellulose is comprised in an amount of 50 to 70 wt% based on the total weight of the first discrete part.
5. The pharmaceutical combination formulation of claim 4, wherein the lactose hydrate and the micro-crystalline cellulose may be employed in a ratio of 1 : 1.5 to 1 :3.
6. The pharmaceutical combination formulation of claim 1, wherein the second discrete part is in the form of granules prepared by a roller compaction process.
7. A fixed-dose combination formulation comprising:
(1) a first discrete part comprising amlodipine or a pharmaceutically acceptable salt thereof, rosuvastatin or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable additive; and
(2) a second discrete part comprising losartan or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable additive,
wherein said discrete parts are physically separated from each other,
8. The fixed-dose combination formulation of claim 7, wherein the amount of amlodipine or a pharmaceutically acceptable salt thereof, as converted to amlodipine free base form, is 5 to 10 mg.
9. The fixed-dose combination formulation of claim 7, wherein the amount of rosuvastatin or a pharmaceutically acceptable salt thereof, as converted to rosuvastatin free acid form, is 10 to 20 mg.
10. The fixed-dose combination formulation of claim 7, wherein the amount of losartan or a pharmaceutically acceptable salt thereof, as converted to losartan free base form, is 45 to 100 mg.
1 1. A method for preparing a pharmaceutical combination formulation, which comprises the steps of:
a) admixing amlodipine or a pharmaceutically acceptable salt thereof, rosuvastatin or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable additive;
b) admixing losartan or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable salt thereof; and
c) loading a discrete part prepared in Step a) and a discrete part prepared in Step b) into a formulation, wherein said discrete parts are physically separated from each other.
12. The method for preparing a pharmaceutical combination formulation of claim 11 , wherein Step b) further comprises a granulizing step, and in Step c) the discrete part obtained in Step a) and the granules obtained in Step b) are tableted to obtain a bilayer tablet.
PCT/KR2014/011205 2013-11-29 2014-11-20 Pharmaceutical combination formulation comprising amlodipine, losartan and rosuvastatin WO2015080433A1 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
UAA201606918A UA120043C2 (en) 2013-11-29 2014-11-20 Pharmaceutical combination formulation comprising amlodipine, losartan and rosuvastatin
US15/039,238 US9833413B2 (en) 2013-11-29 2014-11-20 Pharmaceutical combination formulation comprising amlodipine, losartan and rosuvastatin
EP14866739.7A EP3073998A4 (en) 2013-11-29 2014-11-20 Pharmaceutical combination formulation comprising amlodipine, losartan and rosuvastatin
AU2014354475A AU2014354475B2 (en) 2013-11-29 2014-11-20 Pharmaceutical combination formulation comprising amlodipine, losartan and rosuvastatin
CN201480064825.8A CN105792813B (en) 2013-11-29 2014-11-20 A kind of medicine composition containing Amlodipine, Losartan and rosuvastatin
MX2016006415A MX370041B (en) 2013-11-29 2014-11-20 Pharmaceutical combination formulation comprising amlodipine, losartan and rosuvastatin.
BR112016011603A BR112016011603A2 (en) 2013-11-29 2014-11-20 PHARMACEUTICAL COMBINATION FORMULATION COMPRISING AMLODIPINE, LOSARTAN AND ROSUVASTATIN
CA2929862A CA2929862A1 (en) 2013-11-29 2014-11-20 Pharmaceutical combination formulation comprising amlodipine, losartan and rosuvastatin
RU2016125749A RU2660586C1 (en) 2013-11-29 2014-11-20 Pharmaceutical combination formulation containing amlodipine, losartan and rosuvastatin
JP2016531655A JP6427572B2 (en) 2013-11-29 2014-11-20 Pharmaceutical combination containing amlodipine, losartan and rosuvastatin
PH12016500833A PH12016500833A1 (en) 2013-11-29 2016-05-05 Pharmaceutical combination formulation comprising amlodipine, losartan and rosuvastatin
ZA2016/03272A ZA201603272B (en) 2013-11-29 2016-05-13 Pharmaceutical combination formulation comprising amlodipine, losartan and rosuvastatin
SA516371218A SA516371218B1 (en) 2013-11-29 2016-05-26 Pharmaceutical combination formulation comprising amlodipine, losartan and rosuvastatin

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2013-0147883 2013-11-29
KR1020130147883A KR101910901B1 (en) 2013-11-29 2013-11-29 Pharmaceutical complex formulation comprising amlodipine, losartan and rosuvastatin

Publications (1)

Publication Number Publication Date
WO2015080433A1 true WO2015080433A1 (en) 2015-06-04

Family

ID=53199333

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2014/011205 WO2015080433A1 (en) 2013-11-29 2014-11-20 Pharmaceutical combination formulation comprising amlodipine, losartan and rosuvastatin

Country Status (20)

Country Link
US (1) US9833413B2 (en)
EP (1) EP3073998A4 (en)
JP (1) JP6427572B2 (en)
KR (1) KR101910901B1 (en)
CN (1) CN105792813B (en)
AR (1) AR098417A1 (en)
AU (1) AU2014354475B2 (en)
BR (1) BR112016011603A2 (en)
CA (1) CA2929862A1 (en)
CL (1) CL2016001298A1 (en)
JO (1) JO3557B1 (en)
MX (1) MX370041B (en)
PH (1) PH12016500833A1 (en)
RU (1) RU2660586C1 (en)
SA (1) SA516371218B1 (en)
TW (1) TWI649099B (en)
UA (1) UA120043C2 (en)
UY (1) UY35859A (en)
WO (1) WO2015080433A1 (en)
ZA (1) ZA201603272B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017003186A1 (en) * 2015-06-30 2017-01-05 Hanmi Pharm. Co., Ltd. Pharmaceutical complex formulation comprising amlodipine, losartan and rosuvastatin

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017007287A1 (en) * 2015-07-08 2017-01-12 씨제이헬스케어 주식회사 Pharmaceutical composition containing amlodipine, valsartan, and rosuvastatin
SG11201903132YA (en) * 2016-11-15 2019-05-30 Hanmi Pharmaceutical Co Ltd Pharmaceutical complex preparation comprising amlodipine, losartan and rosuvastatin
KR101920996B1 (en) * 2017-04-26 2018-11-22 알보젠코리아 주식회사 A Complex Formulation Comprising HMG-CoA Reductase Inhibitor and Calcium Channel Blocker
KR20190043076A (en) * 2017-10-17 2019-04-25 한미약품 주식회사 Pharmaceutical composition comprising amlodipine, losartan and rosuvastatin for prevention and treatment of cardiovascular diseases accompanied by diabetes and formulated combination including the same
KR101997652B1 (en) * 2018-01-22 2019-07-08 보령제약 주식회사 Pharmaceutical formulation
KR102569271B1 (en) * 2018-03-19 2023-08-23 한미약품 주식회사 Pharmaceutical combination preparation comprising ezetimibe and rosuvastatin
KR102108396B1 (en) * 2018-04-25 2020-05-07 제일약품주식회사 Pharmaceutical formulation
KR101992400B1 (en) * 2018-04-30 2019-06-24 보령제약 주식회사 Pharmaceutical formulation
KR102500643B1 (en) * 2019-04-18 2023-02-16 한미약품 주식회사 Pharmaceutical combination preparation comprising ezetimibe and losartan
KR102608889B1 (en) * 2020-07-14 2023-12-04 한미약품 주식회사 Pharmaceutical combination preparation comprising proton pump inhibitor and antacid and preparation method thereof
KR20220026641A (en) * 2020-08-25 2022-03-07 주식회사 대웅제약 A single dosage form of a pharmaceutical composition for the treatment or prevention of hypertension and hyperlipidemia
CN116761589A (en) * 2020-12-18 2023-09-15 株式会社大熊制药 New formulations for oral administration containing 1- (5- (2, 4-difluorophenyl) -1- ((3-fluorophenyl) sulfonyl) -4-methoxy-1H-pyrrol-3-yl) -N-methyl methylamine

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5138069A (en) 1986-07-11 1992-08-11 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking imidazoles
US5608075A (en) 1993-12-23 1997-03-04 Merck & Co., Inc. Polymorphs of losartan and the process for the preparation of form II of losartan
EP1314425A1 (en) * 2000-08-30 2003-05-28 Sankyo Company, Limited Medicinal compositions for preventing or treating heart failure
KR100452491B1 (en) 2001-03-29 2004-10-12 한미약품 주식회사 A novel crystalline amlodipine camsylate and a preparing method thereof
WO2009154810A2 (en) * 2008-02-25 2009-12-23 Dr. Reddy's Laboratories Ltd. Delivery systems for multiple active agents
CN101690816A (en) 2009-08-16 2010-04-07 王丽燕 Medicinal composition of calcium-containing antagonist, A II receptor antagonist and statins
KR101160151B1 (en) 2009-01-23 2012-06-27 한미사이언스 주식회사 Solid pharmaceutical composition comprising amlodipine and losartan
WO2013100630A1 (en) * 2011-12-30 2013-07-04 Hanmi Pharm. Co., Ltd. Fixed dose combination formulation comprising losartan, amlodipine and hydrochlorothiazide
WO2013154390A1 (en) * 2012-04-13 2013-10-17 Hanmi Pharm. Co., Ltd. Composite formulation comprising multi-unit spheroidal tablet (must) encapsulated in hard capsule and method for preparing same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS53141B (en) * 2004-11-05 2014-06-30 Boehringer Ingelheim International Gmbh Bilayer tablet comprising telmisartan and amlodipine
KR101247583B1 (en) * 2006-12-08 2013-03-26 한미사이언스 주식회사 Pharmaceutical composition comprising amlodipine or a pharmaceutically acceptable salt thereof and losartan or a pharmaceutically acceptable salt thereof
PL2120878T3 (en) * 2007-02-09 2015-01-30 Alphapharm Pty Ltd A dosage form containing two active pharmaceutical ingredients in different physical forms
US20090093542A1 (en) * 2007-10-04 2009-04-09 Cooper Garth J S Copper antagonist compositions
CN101632672B (en) * 2008-07-24 2011-01-12 鲁南制药集团股份有限公司 Compound medicinal composition for treating hypertension
CN101637609A (en) * 2009-09-06 2010-02-03 王丽燕 Drug composition containing amlodipine, A II receptor antagonist and statins
EP2575757A1 (en) * 2010-06-03 2013-04-10 Mahmut Bilgic Water soluble formulation comprising a combination of amlodipine and a statin

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5138069A (en) 1986-07-11 1992-08-11 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking imidazoles
US5153197A (en) 1986-07-11 1992-10-06 E. I. Du Pont De Nemours And Company Treatment of hypertension with angiotensin II blocking imidazoles
US5608075A (en) 1993-12-23 1997-03-04 Merck & Co., Inc. Polymorphs of losartan and the process for the preparation of form II of losartan
EP1314425A1 (en) * 2000-08-30 2003-05-28 Sankyo Company, Limited Medicinal compositions for preventing or treating heart failure
KR100452491B1 (en) 2001-03-29 2004-10-12 한미약품 주식회사 A novel crystalline amlodipine camsylate and a preparing method thereof
WO2009154810A2 (en) * 2008-02-25 2009-12-23 Dr. Reddy's Laboratories Ltd. Delivery systems for multiple active agents
KR101160151B1 (en) 2009-01-23 2012-06-27 한미사이언스 주식회사 Solid pharmaceutical composition comprising amlodipine and losartan
KR101232296B1 (en) 2009-01-23 2013-02-13 한미사이언스 주식회사 Solid pharmaceutical composition comprising amlodipine and losartan and having an improved stability
CN101690816A (en) 2009-08-16 2010-04-07 王丽燕 Medicinal composition of calcium-containing antagonist, A II receptor antagonist and statins
WO2013100630A1 (en) * 2011-12-30 2013-07-04 Hanmi Pharm. Co., Ltd. Fixed dose combination formulation comprising losartan, amlodipine and hydrochlorothiazide
WO2013154390A1 (en) * 2012-04-13 2013-10-17 Hanmi Pharm. Co., Ltd. Composite formulation comprising multi-unit spheroidal tablet (must) encapsulated in hard capsule and method for preparing same

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
RAMA ET AL.: "Formulation and evaluation of bilayer tablets of two incompatible drugs amlodipine besilate and losartan potassium", INTERNATIONAL RESEARCH JOURNAL OF PHARMACY, vol. 2, no. 9, 13 October 2013 (2013-10-13), pages 136 - 142
RAMA, M. R. B.: "Formulation and evaluation of bilayer tablets of two incompatible drugs amlodipine besilate and losartan potassium", INTERNATIONAL RESEARCH JOURNAL OF PHARMACY, vol. 4, no. 9, September 2013 (2013-09-01), pages 136 - 142, XP055346737 *
See also references of EP3073998A4

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017003186A1 (en) * 2015-06-30 2017-01-05 Hanmi Pharm. Co., Ltd. Pharmaceutical complex formulation comprising amlodipine, losartan and rosuvastatin
CN108156807A (en) * 2015-06-30 2018-06-12 韩美药品株式会社 Medicine compound preparation containing Amlodipine, Losartan and Rosuvastatin
RU2724338C2 (en) * 2015-06-30 2020-06-23 Ханми Фарм. Ко., Лтд. Pharmaceutical complex composition containing amlodipine, losartan and rosuvastatin
CN112933093A (en) * 2015-06-30 2021-06-11 韩美药品株式会社 Pharmaceutical composite preparation containing amlodipine, losartan and rosuvastatin

Also Published As

Publication number Publication date
CL2016001298A1 (en) 2017-01-06
UA120043C2 (en) 2019-09-25
US20170027871A1 (en) 2017-02-02
CN105792813B (en) 2019-11-19
CN105792813A (en) 2016-07-20
TWI649099B (en) 2019-02-01
ZA201603272B (en) 2018-08-29
KR20150067777A (en) 2015-06-19
EP3073998A1 (en) 2016-10-05
RU2660586C1 (en) 2018-07-06
SA516371218B1 (en) 2017-12-21
KR101910901B1 (en) 2018-10-24
CA2929862A1 (en) 2015-06-04
MX2016006415A (en) 2016-07-19
AU2014354475A1 (en) 2016-05-26
TW201609198A (en) 2016-03-16
UY35859A (en) 2015-06-30
MX370041B (en) 2019-11-29
JO3557B1 (en) 2020-07-05
AR098417A1 (en) 2016-05-26
PH12016500833A1 (en) 2016-06-13
JP6427572B2 (en) 2018-11-21
BR112016011603A2 (en) 2022-07-12
US9833413B2 (en) 2017-12-05
EP3073998A4 (en) 2017-05-31
AU2014354475B2 (en) 2019-12-19
JP2017501126A (en) 2017-01-12

Similar Documents

Publication Publication Date Title
US9833413B2 (en) Pharmaceutical combination formulation comprising amlodipine, losartan and rosuvastatin
CA2749903C (en) Solid pharmaceutical composition comprising amlodipine and losartan and process for producing same
EP2037917B1 (en) Pharmaceutical composition comprising amlodipine and losartan
RU2724338C2 (en) Pharmaceutical complex composition containing amlodipine, losartan and rosuvastatin
WO2013100630A1 (en) Fixed dose combination formulation comprising losartan, amlodipine and hydrochlorothiazide
CN108289850B (en) Pharmaceutical composite preparation containing amlodipine, losartan and chlorthalidone
JP2009521526A (en) Combined preparation containing amlodipine cansylate and simvastatin and method for producing the same
AU2011339150B2 (en) Complex formulation comprising lercanidipine hydrochloride and valsartan and method for the preparation thereof
TWI681773B (en) Solid pharmaceutical composition comprising amlodipine and losartan
JP2016514125A (en) Compound preparation containing valsartan and rosuvastatin calcium and method for producing the same

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14866739

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2929862

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 12016500833

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: IDP00201603225

Country of ref document: ID

ENP Entry into the national phase

Ref document number: 2016531655

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: MX/A/2016/006415

Country of ref document: MX

REEP Request for entry into the european phase

Ref document number: 2014866739

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2014866739

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 15039238

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2014354475

Country of ref document: AU

Date of ref document: 20141120

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112016011603

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: A201606918

Country of ref document: UA

WWE Wipo information: entry into national phase

Ref document number: 2016/0558.1

Country of ref document: KZ

ENP Entry into the national phase

Ref document number: 2016125749

Country of ref document: RU

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 112016011603

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20160520

ENPC Correction to former announcement of entry into national phase, pct application did not enter into the national phase

Ref document number: 112016011603

Country of ref document: BR

Kind code of ref document: A2

Free format text: ANULADA A PUBLICACAO CODIGO 1.3 NA RPI NO 2431 DE 08/08/2017 POR TER SIDO INDEVIDA.

REG Reference to national code

Ref country code: BR

Ref legal event code: B01E

Ref document number: 112016011603

Country of ref document: BR

Kind code of ref document: A2

Free format text: ENVIAR NOVAS VIAS DAS REIVINDICACOES EMENDADAS, POIS AS PAGINAS ENVIADAS APRESENTAM AS NUMERACOES 1/ 1, 2/ 1 E 3/1, RESPECTIVAMENTE.

ENP Entry into the national phase

Ref document number: 112016011603

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20160520